Skip to Content
Merck
  • Vasorelaxant activities of Danhong injection and their differential effects on the rat abdominal aorta and mesenteric artery.

Vasorelaxant activities of Danhong injection and their differential effects on the rat abdominal aorta and mesenteric artery.

Journal of cardiovascular pharmacology (2014-09-30)
Xianming Su, Xiaowen Zhi, Ting Cui, Qiaowei Zheng, Shixiang Wang, Yongxiao Cao, Changcong Cui, Weiyi Feng
ABSTRACT

Previous studies have found that Danhong injection (DHI), an extensively used herbal extract preparation in China, might be a powerful vasodilator. The aims of this study were to determine the vascular activity of DHI and its effects on arteries of different sizes. The results showed that DHI significantly inhibited rat-hindquarters and rabbit-ear vasoconstriction elicited by norepinephrine (NE) perfusion and markedly relaxed KCl-contracted and NE-contracted rat abdominal aortic and mesenteric artery rings. The endothelium made only a minor contribution to the vasorelaxant effect of DHI on artery segments. The vasorelaxant effect of DHI varied with the artery size, with larger arteries exhibiting a more sensitive and potent vasodilator response. DHI relaxed NE-induced vasoconstriction probably through inhibition of the intracellular Ca2+ release through the inositol triphosphate receptor system in the abdominal aorta and mesenteric artery, along with blockage of extracellular Ca2+ influx through the receptor-linked Ca2+ channels in the mesenteric artery. In addition, DHI completely relaxed KCl-induced contraction in both of the arteries, suggesting that inhibition of Ca2+ influx through voltage-gated Ca2+ channels is involved in the vasorelaxant effect of DHI. This elucidation of the vascular effects of DHI and the underlying mechanisms could lead to improved clinical applications.

MATERIALS
Product Number
Brand
Product Description

Supelco
Melting point standard 235-237°C, analytical standard
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Triethylamine, for protein sequence analysis, ampule, ≥99.5% (GC)
Sigma-Aldrich
Triethylamine, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Triethylamine, for amino acid analysis, ≥99.5% (GC)
Sigma-Aldrich
Triethylamine, purum, ≥99% (GC)
Sigma-Aldrich
4-Aminopyridine, 98%
Sigma-Aldrich
4-Aminopyridine, ≥99%
Sigma-Aldrich
Acetylcholine bromide, ≥99%
Sigma-Aldrich
Triethylamine, ≥99.5%
Sigma-Aldrich
Triethylamine, ≥99.5%
Sigma-Aldrich
Triethylamine, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
Triethylamine, ≥99%
Phentolamine mesilate, European Pharmacopoeia (EP) Reference Standard
Phentolamine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Triethylamine, analytical standard
Supelco
Phentolamine Mesylate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Atropine Sulfate, Pharmaceutical Secondary Standard; Certified Reference Material
Atropine sulfate, European Pharmacopoeia (EP) Reference Standard
Caffeine, European Pharmacopoeia (EP) Reference Standard
Supelco
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Caffeine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
USP
Caffeine melting point standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Phentolamine methanesulfonate salt, ≥98% (TLC), powder
Sigma-Aldrich
Atropine sulfate salt monohydrate, ≥97% (TLC), crystalline
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous
Sigma-Aldrich
Caffeine, BioXtra
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg